Why the study?
Following the PARADIGM-HF trial, there is growing interest in determining structural changes beyond reverse left ventricular remodelling with sacubitril-valsartan, including whether it alters left atrial mechanics.
Does sacubitril-valsartan improve left atrial mechanics in patients with HFrEF?
Does sacubitril-valsartan improve left atrial mechanics in patients with HFrEF?
Initiation of sacubitril-valsartan in patients with HFrEF is associated with significant improvements in left atrial mechanics and reductions in NT-proBNP at 3 months.
Answers are grounded in this paper and cite their sources.
LA mechanics improved post-sacubitril/valsartan in HFrEF; hypothesis-generating for LA strain as response marker, prospective trials needed before practice change.
Introduction Heart failure with reduced ejection fraction (HFrEF) is associated with significant morbidity and mortality. Recently, in the PARADIGM-HF, sacubitrilvalsartan was superior to enalapril in reducing death and hospitalization for heart failure, and there is a growing interest in determining the structural changes besides reverse left ventricular remodelling. Purpose To determine if, in patients treated with sacubitril-valsartan, there was a change in left atrial (LA) mechanics quantified by two-dimensional strain echocardiography (2D-STE). Methods A total of 38 consecutive patients with HFrEF, followed in an outpatient heart failure clinic, were recruited. Population characteristics are summarized in Table 1. 2D-STE was used to measure left atrial strain in the reservoir phase (LASr) (Figure 1) and strain rate (LA-SR) before and 3 months after initiation of sacubitril-valsartan. Results There was a significant improvement in LASr (11.3±6.5% vs 14.2±7.4%, p=0.006) and LA-SR (0.55±0.25 s-1 vs 0.69±0.31 s-1, p=0.008) after initiation of sacubitril-valsartan. There was also a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (1443.5 pg/ml (Interquartile range [IQR], 772–2912) vs 1112.0 pg/ml (IQR, 510–1455), p=0.016) and a tendency towards reduction in left atrial volume index (LAVI) (54.6±17.0 ml/m2 vs 51.4±18.8 ml/m2, p=0.053). The change in LASr and LA-SR was not related with the dose of sacubitril-valsartan (p=0.089). Conclusion In this population of HFrEF patients LA mechanics, as determined by 2D-STE, as well as NT-proBNP levels, significantly improved after treatment with sacubitril-valsartan.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: